Abstract
Our study aimed to harness the power of CT scans, observed over time, in predicting how lung adenocarcinoma patients might respond to a treatment known as EGFR-TKI. Analyzing scans from 322 advanced stage lung cancer patients, we identified distinct image-based patterns. By integrating these patterns with comprehensive clinical information, such as gene mutations and treatment regimens, our predictive capabilities were significantly enhanced. Interestingly, the precision of these predictions, particularly related to radiomics features, diminished when data from various centers were combined, suggesting that the approach requires standardization across facilities. This novel method offers a potential pathway to anticipate disease progression in lung adenocarcinoma patients treated with EGFR-TKI, laying the groundwork for more personalized treatments. To further validate this approach, extensive studies involving a larger cohort are pivotal.
Original language | English |
---|---|
Article number | 5125 |
Journal | Cancers |
Volume | 15 |
Issue number | 21 |
DOIs | |
State | Published - Nov 2023 |
Keywords
- computer tomography (CT) scans
- delta radiomics signatures
- epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI)
- lung adenocarcinoma
- personalized treatment strategies
- progression-free survival (PFS)
- time-variable radiomics